Merck's Remigromig Meets Primary Endpoint in Diabetic Macular Edema Trial

Merck's investigational tri-specific antibody, remigromig, has achieved its primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for adults with diabetic macular edema.

The drug demonstrated non-inferiority compared to ranibizumab, meeting a key objective of the study. Both the 0.5 mg and 0.8 mg doses of remigromig showed non-inferiority to ranibizumab in measuring best-corrected visual acuity change at week 52.

However, the trial results also revealed higher rates of proliferative diabetic retinopathy, vitreous hemorrhage, and treatment discontinuations due to adverse events among patients receiving remigromig compared to those receiving ranibizumab.